JNJ Stock Hits 38.5% Overvaluation Despite Strong Dividend Profile
Johnson & Johnson (NYSE: JNJ) has received regulatory approval from China's National Medical Products Administration for Icotyde, a daily oral treatment for moderate-to-severe plaque psoriasis. This milestone follows the FDA's earlier endorsement of the drug and positions JNJ in a competitive market alongside AbbVie and Bristol Myers.
The company's dividend yield is 2.0% with a conservative payout ratio of 50% and a solid 3-year dividend growth rate of 4.9%, supporting a sustainable income stream despite the stock trading 38.5% above its GF Value™ intrinsic valuation. The company's GF Score™ stands at a robust 83 out of 100, reflecting strong financial health and profitability, though momentum remains a relative weakness.
Insider activity reveals net selling over the past 12 months with insiders offloading $155.7 million in shares versus only $0.3 million purchased, while 29 premium gurus currently hold JNJ, but 18 have trimmed positions compared to 5 adding recently.